FRAZIER KENNETH C 4

Accession 0001127602-22-024871

CIK 0000310158other

View on SEC.gov Company Profile

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 4:06 PM ET

Size

30.0 KB

Accession

0001127602-22-024871

Insider Transaction Report

Form 4

Period: 2022-11-01

Merck & Co., Inc.MRK

FRAZIER KENNETH C

Exec. VP & President, GHH

Transactions

Exercise/Conversion
Common Stock
2022-11-01+300,000→ 1,006,283.063 total
Sale
Common Stock
2022-11-01$100.22/sh−96,981$9,719,843→ 706,983.063 total
Sale
Common Stock
2022-11-01$101.05/sh−700$70,733→ 706,283.063 total
Gift
Common Stock
2022-11-01−2,450→ 702,123.063 total
Gift
Common Stock
2022-11-01−1,470→ 700,653.063 total
Exercise/Conversion
Common Stock
2022-11-02+165,828→ 866,481.063 total
Exercise/Conversion
Common Stock
2022-11-02+134,172→ 1,000,653.063 total
Sale
Common Stock
2022-11-01$99.61/sh−202,319$20,152,287→ 803,964.063 total
Gift
Common Stock
2022-11-01−1,710→ 704,573.063 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-11-01−300,000→ 165,828 total
Exercise: $58.08From: 2016-05-01Exp: 2025-04-30→ Common Stock (300,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-11-02−165,828→ 0 total
Exercise: $58.08From: 2016-05-01Exp: 2025-04-30→ Common Stock (165,828 underlying)
Sale
Common Stock
2022-11-02$99.68/sh−205,661$20,500,103→ 794,992.063 total
Sale
Common Stock
2022-11-02$100.40/sh−94,339$9,471,739→ 700,653.063 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-11-02−134,172→ 705,769 total
Exercise: $53.06From: 2017-05-10Exp: 2026-05-09→ Common Stock (134,172 underlying)

Holdings

Common Stock - 401(k) Plan
(indirect: By 401(k))
4,481.129

Footnotes (10)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9700 to $99.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F10]The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.9800 to $100.9800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.0300 to $101.0700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0000 to $100.0000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.0100 to $101.0100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
[F6]Holdings include shares acquired in dividend reinvestment transactions.
[F7]Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.
[F8]The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018.
[F9]Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Merck & Co., Inc.

CIK 0000310158

→

Entity typeother

Related Parties

filerCIK 0001181175

Filing Metadata

Form type: 4
Filed: Nov 2, 8:00 PM ET
Accepted: Nov 3, 4:06 PM ET
Size: 30.0 KB

View on SEC.gov